Multibiomarker disease activity score and C-reactive protein in a cross-sectional observational study of patients with rheumatoid arthritis with and without concomitant fibromyalgia
- PMID: 26608972
- PMCID: PMC4795537
- DOI: 10.1093/rheumatology/kev388
Multibiomarker disease activity score and C-reactive protein in a cross-sectional observational study of patients with rheumatoid arthritis with and without concomitant fibromyalgia
Abstract
Objectives: To examine the association between a multibiomarker disease activity (MBDA) score, CRP and clinical disease activity measures among RA patients with and without concomitant FM.
Methods: In an observational cohort of patients with established RA, we performed a cross-sectional analysis comparing MBDA scores with CRP by rank correlation and cross-classification. MBDA scores, CRP and clinical measures of disease activity were compared between patients with RA alone and RA with concomitant FM (RA and FM) by univariate and multivariate analyses.
Results: CRP was ⩽1.0 mg/dl for 184 of 198 patients (93%). MBDA scores correlated with CRP (r = 0.755, P < 0.001), but were often discordant, being moderate or high for 19%, 55% and 87% of patients with CRP ⩽0.1, 0.1 to ⩽0.3, or 0.3 to ⩽1.0 mg/dl, respectively. Among patients with CRP ⩽1.0 mg/dl, swollen joint count (SJC) increased linearly across levels of MBDA score, both with (P = 0.021) and without (P = 0.004) adjustment for CRP, whereas CRP was not associated with SJC. The 28-joint-DAS-CRP, other composite measures, and their non-joint-count component measures were significantly greater for patients with RA and FM (n = 25) versus RA alone (n = 173) (all P ⩽ 0.005). MBDA scores and CRP were similar between groups.
Conclusion: MBDA scores frequently indicated RA disease activity when CRP did not. Neither one was significantly greater among patients with RA and FM versus RA alone. Thus, MBDA score may be a useful objective measure for identifying RA patients with active inflammation when CRP is low (⩽1.0 mg/dl), including RA patients with concomitant FM.
Keywords: C-reactive protein; RAPID3; biomarkers; disease activity; fibromyalgia; multibiomarker; rheumatoid arthritis.
© The Author 2015. Published by Oxford University Press on behalf of the British Society for Rheumatology.
Figures


Similar articles
-
Correlation of the Multi-Biomarker Disease Activity Score With Rheumatoid Arthritis Disease Activity Measures: A Systematic Review and Meta-Analysis.Arthritis Care Res (Hoboken). 2019 Nov;71(11):1459-1472. doi: 10.1002/acr.23785. Arthritis Care Res (Hoboken). 2019. PMID: 30320973 Free PMC article.
-
Interpreting the multi-biomarker disease activity score in the context of tocilizumab treatment for patients with rheumatoid arthritis.Rheumatol Int. 2016 Feb;36(2):295-300. doi: 10.1007/s00296-015-3285-2. Epub 2015 May 31. Rheumatol Int. 2016. PMID: 26026604 Free PMC article. Clinical Trial.
-
Relationship of multi-biomarker disease activity score and other risk factors with radiographic progression in an observational study of patients with rheumatoid arthritis.Rheumatology (Oxford). 2016 Feb;55(2):357-66. doi: 10.1093/rheumatology/kev341. Epub 2015 Sep 18. Rheumatology (Oxford). 2016. PMID: 26385370 Free PMC article.
-
Influence of obesity, age, and comorbidities on the multi-biomarker disease activity test in rheumatoid arthritis.Semin Arthritis Rheum. 2018 Feb;47(4):472-477. doi: 10.1016/j.semarthrit.2017.07.010. Epub 2017 Aug 2. Semin Arthritis Rheum. 2018. PMID: 28947312
-
Multibiomarker disease activity score: an objective tool for monitoring rheumatoid arthritis? A systematic review and meta-analysis.Rheumatology (Oxford). 2023 Jun 1;62(6):2048-2059. doi: 10.1093/rheumatology/keac715. Rheumatology (Oxford). 2023. PMID: 36575983 Free PMC article.
Cited by
-
The multi-biomarker disease activity score tracks response to rituximab treatment in rheumatoid arthritis patients: a post hoc analysis of three cohort studies.Arthritis Res Ther. 2018 Nov 20;20(1):256. doi: 10.1186/s13075-018-1750-5. Arthritis Res Ther. 2018. PMID: 30458871 Free PMC article.
-
Association Between Pain Sensitization and Disease Activity in Patients With Rheumatoid Arthritis: A Cross-Sectional Study.Arthritis Care Res (Hoboken). 2018 Feb;70(2):197-204. doi: 10.1002/acr.23266. Arthritis Care Res (Hoboken). 2018. PMID: 28437846 Free PMC article.
-
Correlation of the Multi-Biomarker Disease Activity Score With Rheumatoid Arthritis Disease Activity Measures: A Systematic Review and Meta-Analysis.Arthritis Care Res (Hoboken). 2019 Nov;71(11):1459-1472. doi: 10.1002/acr.23785. Arthritis Care Res (Hoboken). 2019. PMID: 30320973 Free PMC article.
-
Multi-biomarker disease activity score as a predictor of disease relapse in patients with rheumatoid arthritis stopping TNF inhibitor treatment.PLoS One. 2018 May 23;13(5):e0192425. doi: 10.1371/journal.pone.0192425. eCollection 2018. PLoS One. 2018. PMID: 29791439 Free PMC article. Clinical Trial.
-
Multimorbidity Patterns and Rheumatoid Arthritis Disease Outcomes: Findings From a Multicenter, Prospective Cohort.Arthritis Care Res (Hoboken). 2025 Mar;77(3):337-348. doi: 10.1002/acr.25184. Epub 2023 Oct 30. Arthritis Care Res (Hoboken). 2025. PMID: 37394710 Free PMC article.
References
-
- Brown AK, Conaghan PG, Karim Z. et al. An explanation for the apparent dissociation between clinical remission and continued structural deterioration in rheumatoid arthritis. Arthritis Rheum 2008;58:2958–67. - PubMed
-
- Crowson CS, Rahman MU, Matteson EL. Which measure of inflammation to use? A comparison of erythrocyte sedimentation rate and C-reactive protein measurements from randomized clinical trials of golimumab in rheumatoid arthritis. J Rheumatol 2009;36:1606–10. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous